Avenue Therapeutics (ATXI) AI Stock Analysis

• Market Cap: $1.48M
• Dividend Yield: N/A
• Average Volume (3M): 2.90K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.71
• Revenue Growth: N/A
• EPS Growth: 89.68%
• Country: US
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 3,294,635
• 10 Day Avg. Volume: 2,401
• 30 Day Avg. Volume: 2,901
• PEG Ratio: -0.22
• Price to Book (P/B): 1.16
• Price to Sales (P/S): 1.52
• P/FCF Ratio: -1.16
• Enterprise Value/Market Cap: -0.93
• Enterprise Value/Revenue: -0.98
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: 0.42
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: $0.46 ▼(-37.40% Downside)
• Action: Reiterated Date: 04/11/26
• Date: Action: Reiterated 04/11/26

The score is primarily constrained by ongoing losses, negative cash flow, and limited balance-sheet capacity despite improved 2025 results and zero debt. Technicals are supportive in the short term but look overextended and still below the 200-day trend. A positive licensing event adds upside potential, while valuation signals are limited due to a negative P/E and no dividend.

Positive Factors

Low Leverage

Zero total debt materially reduces financial risk for a small biotech that will need capital to advance programs. Low leverage preserves optionality to pursue non-dilutive deals or controlled financings, and limits interest burden, improving flexibility to prioritize development or licensing choices over the next several quarters.

Negative Factors

Negative Cash Flow

Persistent negative operating and free cash flow means Avenue must rely on external capital to fund development. Over multiple quarters this raises dilution and execution risk, and constrains the company’s ability to independently advance late-stage trials or manufacturing commitments without partner support or fresh financing.

Avenue Therapeutics Business Overview & Revenue Model

Company Description

Avenue Therapeutics (ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases. The company's core product includes intravenous (IV) tramadol, whi...

Read more

Avenue Therapeutics (ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases. The company's core product includes intravenous (IV) tramadol, whi...

How the Company Makes Money

null...

Avenue Therapeutics Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.40M	0.00	0.00	0.00	0.00
Gross Profit	1.40M	0.00	0.00	0.00	0.00
EBITDA	-3.29M	-11.70M	4.05M	-2.44M	7.00K
Net Income	-2.91M	-11.65M	-10.38M	-3.55M	-3.73M
Balance Sheet
Total Assets	2.93M	2.67M	1.85M	6.84M	3.96M
Cash, Cash Equivalents and Short-Term Investments	2.85M	2.59M	1.78M	6.71M	3.76M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	1.10M	816.00K	1.20M	3.58M	509.00K
Stockholders Equity	1.83M	2.80M	1.58M	3.90M	3.45M
Cash Flow
Free Cash Flow	-1.83M	-9.03M	-12.45M	-7.60M	-3.75M
Operating Cash Flow	-1.83M	-9.03M	-9.45M	-7.60M	-3.75M
Investing Cash Flow	0.00	0.00	-3.00M	0.00	0.00
Financing Cash Flow	2.09M	9.84M	7.53M	10.54M	4.38M

Avenue Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.73
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATXI, the sentiment is Positive. The current price of 0.73 is above the 20-day moving average (MA) of 0.30, above the 50-day MA of 0.25, and above the 200-day MA of 0.53, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 72.74 is Negative, neither overbought nor oversold. The STOCH value of 90.69 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATXI.

Avenue Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ATXI	53 Neutral	$1.48M	-0.75	-121.42%	―	―	89.68%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SCNI	44 Neutral	$2.01M	-0.20	―	―	178.82%	-4121.10%
BDRX	43 Neutral	$1.52M	-0.19	-63.03%	―	-100.00%	86.75%
OGEN	―	$2.61M	-0.17	-168.95%	―	―	90.27%

Avenue Therapeutics Corporate Events